-
The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC
Time of Update: 2021-06-22
ORIENT-12 is the world's first PD-1 monoclonal antibody combined with gemcitabine and platinum (GP regimen) for advanced sqNSCLC A randomized, double-blind, phase III controlled clinical study of first-line treatment .
-
Li Haibing, deputy general manager of Beilu Pharmaceutical, resigns
Time of Update: 2021-06-22
Li Haibing and applied for resignation from his position as deputy general manager .
Li Haibing's resignation report will take effect from the date of delivery to the company's board of directors, and his resignation will not affect the company's normal operations .
-
The Central Procurement of the Chinese Patent Medicine Alliance will be launched: Is the price cut coming?
Time of Update: 2021-06-22
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
-
ASCO annual meeting grand opening!
Time of Update: 2021-06-22
According to reports, the RATIONALE 302 study is a randomized, open, multi-center, global phase 3 clinical trial designed to evaluate tislelizumab versus chemotherapy selected by investigators as the second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma Effectiveness and safety .
-
10 Chinese products are shortlisted for the new crown antigen reagent list of the British Ministry of Health
Time of Update: 2021-06-22
The updated list shows that 24 new coronavirus antigen reagents have passed the verification, and 10 of them are manufactured by Chinese companies, including Oriental Bio, Deep Blue Medical, Daiernuosi, Shuo Shi biological, Acon biology, biotechnology and other egg-based products .
-
After the "V" reversal of the Chinese medicinal material market, the market speeds up!
Time of Update: 2021-06-22
Epimedium, the recent increase in shipments, find goods business and more stable sources move around, hold stocks were reluctant to sell mentality continues to strengthen, prices firm up, the current origin of new stock price of 100 yuan / kg, the market price and the basic origin Flat .
-
Eli Lilly's oral JAK inhibitor Olumiant effectively improves pain / body function / morning stiffness of joints
Time of Update: 2021-06-22
Olumiant is a tyrosine protein kinase (JAK) 1/2 inhibitor, administered orally once a day, suitable for moderate to severe patients with poor efficacy or intolerance to one or more disease-improving anti-rheumatic drugs (DMARD) Adult patients with active rheumatoid arthritis can be used in combination with methotrexate or other non-biological anti-rheumatic drugs .
-
Qinhao Pharmaceutical obtained the first IND approval in China
Time of Update: 2021-06-22
The clinical approval of this drug means that Qin Hao Pharmaceutical has obtained the first IND approval in China .
-
The second in the country!
Time of Update: 2021-06-22
Hisun won the first imitationHisun won the first imitationAccording to the official website of CDE, a total of 5 companies have submitted applications for the listing of lurasidone hydrochloride tablets for generic drugs.
-
Initiation of triple immunization program clinical trial for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin
Time of Update: 2021-06-22
It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex .
-
The US FDA accelerates the approval of innovative treatments for Alzheimer's disease!
Time of Update: 2021-06-22
Although at the meeting of the Peripheral and Central Nervous System Drug Advisory Committee in November 2020, the experts of the committee had different voices on the clinical benefits, but based on clinical trials, it is clear that the use of Aduhelm treatment can significantly reduce amyloid plaques In the end, the US FDA followed the institutional process of the accelerated approval mechanism and determined that Aduhelm met the regulatory requirements for accelerated approval .
-
2020 Statistical Communiqué on the Development of National Medical Security Undertakings
Time of Update: 2021-06-22
4% of the year’s GDP; the total expenditure of the national basic medical insurance fund (including maternity insurance) was 21,032 billion yuan, a year-on-year increase of 1.
-
CGRP-targeted migraine drug head-to-head study Eli Lilly launches Phase IV clinical trial of Emgality
Time of Update: 2021-06-22
On Tuesday, the company announced that in order to advance the science of migraine treatment and help understand the role of CGRP monoclonal antibodies (mAbs) and oral CGRP receptor antagonists in preventing migraines, it will conduct a head-to-head study.
-
Beijing's 350-meter pharmacy limit canceled!
Time of Update: 2021-06-22
, The distance to existing pharmacies is no longer a condition for permit review .
It is reported that this is after Shanghai this year, another super first-tier city has cancelled the distance limit for pharmacies .
-
Children of 1.65 million illegally bought their own stocks, vice president of Ogilvy Medical receives supervision letter
Time of Update: 2021-06-22
The Shenzhen Stock Exchange pointed out that Du Xianju, as a director and senior manager of the company, failed to urge his children to compliantly trade company stocks, and violated Article 1.
-
U.S. FDA accepts a new generation of PI3Kδ inhibitor/new CD20 monoclonal antibody combination
Time of Update: 2021-06-22
S. Food and Drug Administration (FDA) has accepted a biological product license application (BLA) for ublituximab, combined with Ukoniq (umbralisib) (U2 program), for the treatment of chronic lymphocytic leukemia (CLL) and small cells Patients with lymphoma (SLL) .
-
Jingfeng Pharmaceutical's gemcitabine hydrochloride for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-22
Gemcitabine hydrochloride for injection is mainly suitable for the treatment of locally advanced or metastatic non-small cell lung cancer or pancreatic cancer.
At present, the main domestic manufacturers include Nanjing Zhengda Tianqing Pharmaceutical Co.
, Qilu Pharmaceutical Co.
-
Hengrui PD-1 new indication approved: first-line treatment of nasopharyngeal carcinoma
Time of Update: 2021-06-22
2) has been approved by the NMPA .
The approved indications are: combined cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
This is the sixth indication approved for Karelizumab .
-
U.S. FDA approves Nuzyra (Omacycline) for oral administration only
Time of Update: 2021-06-22
Recently, the FDA also approved Nuzyra's oral dosing regimen for the treatment of acute bacterial skin and skin tissue infections (ABSSSI) in adult patients .
The drug is a modern tetracycline antibiotic that is administered orally or intravenously once a day for the treatment of CABP and ABSSSI .
-
The national drug procurement with volume has entered the era of "big merger" competition!
Time of Update: 2021-06-22
2 requires exploring the merger of different generic drugs with similar indications or functions and indications to carry out centralized and high-volume procurement .
